Press Room

Raquel Barros speaker at the Web Summit 2021

Start
Wednesday, November 03, 2021 - 10:30
End
Wednesday, November 03, 2021 - 10:30
Location: Lisbon, Portugal
Speakers group photo at Web Summit Hovione present to talk about Sustainability | Hovione

Making the best use of Science and Innovative Technologies, we strive to give back to society.

We were present at the Web Summit ? Europe’s largest tech conference.





 

Our scientist Raquel Barros was a guest speaker at the Casa do Impacto booth to talk about Sustainability at Hovione and to launch the Triggers, a startup acceleration program in the sustainability area.


raquel barros speaker at web summit | Hovione



 

 

Learn more about Sustainability at Hovione







 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026